Monoclonals antibodies: A recent and major therapeutic advance;Les anticorps monoclonaux : une avancée thérapeutique récente et majeure

Therapie

Volumn 64, Issue 1, 2009, Pages 1-7

  Paintaud, Gilles ^a,b,c   Lejarre, Fabien ^c   Ternant, David ^a,b,c   Goupille, Philippe ^a,b,c   Watier, Hervé ^a,b,c  

^a UNIVERSITÉ DE TOURS   (France)

^b CNRS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Immunoglobulin G; Immunotherapy; Monoclonal antibodies; Review

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; THYMOCYTE ANTIBODY; TOSITUMOMAB I 131; TRASTUZUMAB;

BIOTECHNOLOGY; CHRONIC DISEASE; DRUG EFFICACY; DRUG MECHANISM; IMMUNOGENICITY; INFLAMMATORY DISEASE; MURINAE; NEOPLASM; PRIORITY JOURNAL; REVIEW;

EID: 67650297541     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2009008     Document Type: Article

References (28)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7
2. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994; 15: 42-52
3. Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635-42 Epub 2004 Jun 2629
4. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803-43
5. Edwards JC, Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 2005; 44: 151-156 Epub 2004 Oct 2027
6. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-88
7. Church AC. Clinical advances in therapies targeting the interleukin-2 receptor. QJM 2003; 96: 91-102
8. Sorensen PS. Multiple sclerosis: pathophysiology revisited. Lancet Neurol 2005; 4: 9-10
9. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35
10. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76
11. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9
12. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-52
13. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004; 27: 307-24
14. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703
15. Chung Ch, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358: 1109-17
16. Agero Al, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad dermatol 2006; 55: 657-70
17. Fracasso PM, Burris H 3rd, Arquette MA, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007; 13: 986-93
18. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601-8
19. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2002; 46: 1451-9
20. Martin S, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43: 16-24
21. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42
22. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophtalmology 2006; 113: 363-72 e5. Epub 2006
23. DuBuske LM. IgE, allergic diseases, and omalizumab. Curr Pharm Des 2006; 13: 3929-44
24. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med 2005; 353: 414-6
25. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6
26. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355: 735-40
27. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2: 52-62
28. Reichert J, Pavolu A. Monoclonal antibodies market. Nat Rev Drug Discov 2004; 3: 383-4